Shandong Boan Biotechnology Co (FRA:UJ9) Research & Development: €17.87 Mil (TTM As of Dec. 2025)


FRA:UJ9 Shandong Boan Biotechnology Co Ltd FRA:UJ9
44 GF Score
Price €0.50
GF Value €1.69
! 5 Warning Signs
View Full Analysis

What is Shandong Boan Biotechnology Co Research & Development?

Shandong Boan Biotechnology Co FRA:UJ9 -0.99% 44 Research & Development is €17.87 Mil as of Dec. 2025. GuruFocus rates FRA:UJ9 with a GF Score™ of 44/100 and a GF Value™ of €1.69. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Shandong Boan Biotechnology Co's Research & Development for the six months ended in Dec. 2025 was €10.80 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €17.87 Mil.

Shandong Boan Biotechnology Co  (FRA:UJ9) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shandong Boan Biotechnology Co Research & Development Related Terms

Shandong Boan Biotechnology Co Research & Development Historical Data

* Premium members only.

The historical data trend for Shandong Boan Biotechnology Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Boan Biotechnology Co Research & Development Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 32.18 54.21 29.63 19.58 17.90

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 13.44 10.99 8.33 7.07 10.80
FRA:UJ9
44GF Score
Shandong Boan Biotechnology Co Ltd FRA:UJ9
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Boan Biotechnology Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €17.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €17.87 Mil mean?
Shandong Boan Biotechnology Co (FRA:UJ9) has a Research & Development of €17.87 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Shandong Boan Biotechnology Co and its competitors.
Is Shandong Boan Biotechnology Co's Research & Development too high?
Shandong Boan Biotechnology Co's current Research & Development is €17.87 Mil. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's Research & Development compare to VRTX and REGN?
Shandong Boan Biotechnology Co's Research & Development of €17.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Shandong Boan Biotechnology Co and its competitors. Shandong Boan Biotechnology Co's current Research & Development is €17.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current Research & Development of €17.87 Mil. The stock's GF Value™ is €1.69, compared to a current price of €0.50 — trading 70.4% below its estimated fair value. The current Research & Development is €17.87 Mil. Shandong Boan Biotechnology Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current Research & Development is €17.87 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued. The current stock price of €0.50 is trading 70.4% below its estimated GF Value™ of €1.69.

Key valuation signals for FRA:UJ9:

  • Research & Development: €17.87 Mil
  • GF Value™: €1.69 vs. price of €0.50 (70.4% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shandong Boan Biotechnology Co Business Description

Other Exchanges 06955:Hong Kong
Address No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score

Get the complete analysis for FRA:UJ9

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.50
Price
€1.69
GF Value